Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374937 | 0.73 | — | — | |
| SCHEMBL22265675 | 0.70 | — | — | |
| SCHEMBL375563 | 0.70 | — | — | |
| SCHEMBL134965 | 0.68 | TRIM24 (0.35) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL3674258 | 0.67 | KCNH2 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL28272321 | 0.67 | TRIM24 (0.33) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL3585294 | 0.67 | — | — | |
| SCHEMBL19200430 | 0.67 | HSD11B1 (0.37) | MEN1CYP2C9KMT2A | |
| SCHEMBL1813694 | 0.65 | TRIM24 (0.38) | TRIM24TRIM33 | |
| SCHEMBL8263587 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3822274-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3204386-B1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-2121691-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2044016-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008119716-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008101660-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101659-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | MEN1 494/4885CYP2C9 1907/4885KMT2A 382/4885 |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | MEN1 494/4885CYP2C9 1907/4885KMT2A 382/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | MEN1 494/4885CYP2C9 1907/4885KMT2A 382/4885 |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | MEN1 494/4885CYP2C9 1907/4885KMT2A 382/4885 |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | MEN1 494/4885CYP2C9 1907/4885KMT2A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.